

## **Centre For AIDS Reagents**

## **Data Sheet**

REAGENT:	J-Lat Tat-GFP Cells (H2)
<b>REPOSITORY REFERENCE:</b>	100 947
PROVIDED:	1 mL at 7.7 x $10^6$ cells. Viability = 79%.
LOT NUMBER:	150246
<b>RELEASE RESTRICTION:</b>	NIH category C
STORAGE:	Liquid nitrogen
DESCRIPTION:	These cells are Jurkat cells that bear the integrated retroviral construct LTR-Tat-IRES-GFP.
SPECIAL CHARACTERISTICS:	Jurkat cells were infected with viral particles bearing the retroviral construct LTR-Tat-IRES-GFP. Cells that were GFP negative, but could be stimulated to express GFP were selected. For the other similar cell, please see 100941-100948.
CELL TYPE:	Jurkat - T lymphocyte cell line
FREEZE MEDIUM:	FBS, 90%; DMSO, 10%.
GROWTH CHARACTERISTIC:	No special requirements, split 1:3 at $1 \times 10^6$ cells/ml. Cells grow in suspension, usually singly but some clumping has been noted.
PROPAGATION MEDIUM:	RPMI 1640, 90%; FBS, 10%; supplemented with penicillin G (100 U/ml), streptomycin (100 $\mu$ g/ml), L-glutamine (2 mM, 0.3 mg/ml).
MORPHOLOGY:	Small, spherical cells in suspension. Morphology usually does not vary.
CONTRIBUTOR:	Dr. Eric Verdin.
<b>REFERENCES:</b>	Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. <i>EMBO J</i> <b>22</b> :1868-1877, 2003.
	Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. <i>EMBO</i> J <b>20</b> :1726-1738, 2001.



## **ACKNOWLEDGMENT:**

The following reagent was obtained by CFAR – NIBSC via the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: J-Lat Tat-GFP (clone #) from Dr. Eric Verdin. Also include the references cited above in any publication.
Please ensure that you send us a copy of any papers Resulting from work using reagents acquired through CFAR, this can be by e-mail or printed copy.